Actelion Pharmaceuticals Ltd

Other

Metys Pharmaceuticals Ag

Michael Scherz

Oliver Nayler

Claus Mueller

Boris Mathys

Christoph Binkert

Martin Bolli

Thomas Weller

Martine Clozel

Beat Steiner

Jasper Dingemanse

Patrick Brossard

Hamed Aissaoui

Daniel Bur

Carlo Farina

Walter Fischli

David Lehmann

Jörg Velker

Carla Ghelardini

Joerg Velker

J&ouml;rg Velker

Nayler Oliver

The present invention relates to a composition of enantiomers of 3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

Synergistic compositions comprising (R)-dimiracetam (1) and (S)-dimiracetam (2) in a non-racemic ratio

The present invention relates to a dosing regimen for a selective S1Preceptor agonist, whereby the selective S1Preceptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1Preceptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1Preceptor agonist.

Dosing regimen for a selective S1Pagonist

[object Object]

The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.

Thiazolidin-4-one-derivatives

Thiazolidin-4-one derivatives

Dosing regimen for a selective S1P1 receptor agonist

Thiazolidin 4-one derivatives

The invention relates to novel pyridine derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

Pyridine derivatives

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.

Thiophene derivatives

The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4- one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.

Growing community of inventors

Ettingen, Switzerland

Michael Scherz